Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Gynecologic 1Genitourinary 1Breast 1

Conditions

Breast Neoplasms 3Breast Neoplasms, Male 2Sarcoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Leiomyoma 1Gulf War Illness 1Fallopian Tube Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Doxorubicin 27Cyclophosphamide 26Radiotherapy 16Gemcitabine 16Filgrastim 11pembrolizumab 10pazopanib 10Radiation 9Docetaxel 9Cisplatin 9fludarabine 7Trabectedin 7Ipilimumab 7Ifosfamide 7Granulocyte Colony-Stimulating Factor 7Etoposide 7Carboplatin 7Busulfan 7Bevacizumab 7olaratumab 6Temozolomide 6Peripheral Blood Stem Cell Transplantation 6Nivolumab 6Mesna 6Melphalan 6selinexor 5Leucovorin 5Irinotecan 5Celecoxib 5Bortezomib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Sarcoma × Mifepristone × Clear all
NCT02014337 2018-01-17

Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors

Corcept Therapeutics

Phase 1 Completed
37 enrolled
BreastGenitourinaryGynecologicSarcomaThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡